Agenda
| 3:00 PM - 3:30 PM |
Registration and Networking |
| 3:30 PM - 5:00 PM |
Industry Panel |
| 5:00 PM - 6:30 PM |
Networking Reception |
Everyone is talking about innovation. The innovation gap, the importance of innovation, can big companies be innovative, is Silicon Valley still the home of innovation? This panel discussion will feature representatives from BIG BioPharma who will share their efforts to stay on top of the innovation game and how you can participate. Featured initiatives will include grants, venture arms, incubators, funding early stage research, interfacing with VCs and much more. Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Networking Reception.
SPEAKER
Christopher Haskell, PhD, Head, US Science Hub, Bayer HealthCare Pharmaceuticals
Sylvaine Cases, Ph.D. Sanofi-Aventis US, External Innovation
Yael Weiss, PhD, Director, Licensing & External Research, Merck Research Laboratories
Thomas F. Zioncheck, Ph.D, Senior Director, Business Development, Genentech
Ang�le Maki, Ph.D, Director, Strategic Transactions Group,Bristol-Myers Squibb Company
Lead Facilitator: Scott M. Iyama, Corporate Senior Associate, Orrick, Herrington & Sutcliffe LLP
Cost & Registration
Regular Price: $50
Partners' Network: $40
Meet with Alumni: $30
Student: $20
BioCenter Members: Free (please RSVP to
[email protected])
VENUE
SPEAKER BIOS
Yael Weiss, PhD, Director, Licensing & External Research, Merck Research Laboratories
Dr. Weiss completed her MSc and PhD in molecular genetics at the Weizmann Institute of Science, Rehovot, Israel and obtained her medical degree at Hadassah Medical Center, affiliated with The Hebrew University of Jerusalem, Israel. After practicing medicine for a few years, Dr. Weiss joined an Israeli venture capital firm as a vice president responsible for analyzing and maintaining deal flow, and then moved on to become a medical and business development director at Genzyme Israel. Dr. Weiss joined Merck's Israeli subsidiary as medical director in the beginning of 2004 and this summer joined Merck's Licensing group in San Francisco as a scientific scout responsible for identification of licensing opportunities emanating from the West Coast
Thomas F. Zioncheck, Ph.D, Senior Director, Business Development, Genentech
Tom Zioncheck has worked in the biopharmaceutical field for over 20 years. He currently serves as Senior Director in the Business Development Group at Genentech where he is responsible for in-licensing new therapeutics and technology in the areas of Ophthalmology, Neuroscience, Cardiovascular and Metabolic Disease.
Tom initially joined Genentech in 1988 as a Postdoctoral Fellow. In 1991 he accepted a Scientist position in drug development. He was subsequently promoted into various positions of increasing responsibility including Sr. Scientist, Director, and Project Team Leader. During the course of his career he has made numerous drug development contributions, co-authored over 30 scientific papers, and is listed as co-inventor on six patents. In his Business Development role, Tom has led multiple development assessments and negotiations resulting in more than 15 significant licensing transactions including both preclinical and clinical-stage development programs.
Tom�s commitment and contribution to the biopharmaceutical industry are further demonstrated by his role in various organizations, including the American Association of Pharmaceutical Scientists (AAPS). In 2001, he was elected Chair for the AAPS Biotech Section and he served as co-chair for the first National AAPS Biotechnology meeting. In 2002, he was appointed as Adjunct Professor in the Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, in Stockton CA.
Tom completed his undergraduate degree in Chemistry at the State University of New York at Oneonta and his Ph.D. in Biochemistry from Purdue University in Indiana.
Christopher Haskell, PhD, Head, US Science Hub, Bayer HealthCare Pharmaceuticals
Coming soon.
Scott M. Iyama, Corporate Senior Associate, Orrick, Herrington & Sutcliffe LLP
Scott Iyama, a corporate managing associate in Orrick's Silicon Valley office, is a member of the Emerging Companies Group, which advises emerging companies and venture capital firms. Mr. Iyama's practice focuses on the representation of emerging growth life science and high tech companies, as well as public offerings, private venture financings and technology transactions.
Some of Mr. Iyama�s current and former clients include:
- AcroMetrix (funded by Telegraph Hill Partners).
- CELLective Dx (funded by Mohr Davidow Ventures and others).
- Facebook (funded by Accel Partners, Greylock, Meritech, Peter Thiel and others).
- Google (NASDAQ: GOOG).
- Greenplum (funded by Meritech, Sierra, Mission and others).
- Halcyon Molecular (funded by Founders' Fund).
- Laserscope (acquired by American Medical Systems Holdings).
- LS9 (funded by Flagship Ventures, Khosla Ventures and Lightspeed Venture Partners).
- Meebo (funded by Sequoia Capital).
- Medsphere (funded by Thomas Weisel Venture Partners, Azure Capital, and Wasatch Venture Fund).
- Micrus Endovascular (NASDAQ: MEND).
- PathoLase (funded by Nexus Medical Partners).
- Sharpcast (funded by Sigma, Selby and Draper Fisher Jurvetson).
- SquareOne (funded by Three Arch Partners, ONSET and others).
- Vendavo (funded by Sigma Partners, Doll Capital Management, InterWest Partners and others).
- VideoEgg (funded by August Capital and others).
Mr. Iyama has also represented Benchmark Capital, De Novo Ventures, Kleiner Perkins Caufield & Byers, Maveron, Montreux Equity Partners, Telegraph Hill Partners and other venture funds in various investments.
Prior to receiving his juris doctor from Stanford Law School, Mr. Iyama performed extensive biochemical research at the University of California, San Diego and Genentech, Inc.
Mr. Iyama frequently lectures on topics related to emerging growth companies at various forums and has given guest lectures at Stanford Law School and Stanford University.
Ang�le Maki, Ph.D., Director, Strategic Transactions Group, Bristol-Myers Squibb Company
Ang�le Maki is a Director in BMS� Strategic Transactions Group where she is responsible for in-licensing and out-licensing of technologies related to discovery and development of biologics. Prior to BMS, Dr. Maki was in Business Development at Medarex, Inc., a biopharmaceutical company focused on fully-human antibody therapeutics. She started at Medarex in 2004 and worked there until it was acquired by BMS in 2009. During her business development and licensing tenure, she has successfully negotiated numerous transactions, from early-stage research to clinical-stage assets.
Dr. Maki received a Ph.D. in biological chemistry from Stanford University and completed postdoctoral work in molecular biology at the Scripps Research Institute in La Jolla. She completed her B.Sc. in chemistry at the University of Winnipeg, in Canada.
Sylvaine Cases, Ph.D.
Sylvaine is currently Director of External Innovation in the sanofi-aventis department of Prospective & Strategic Initiatives. In this position, she is responsible for various scouting and partnering activities with academic centers and biotech in the Bay Area as well as the Oregon and Washington states.
Prior to joining sanofi-aventis, Sylvaine has been working for 16 years in the San Francisco Bay area in academia and biotechnology and her experience covers basic and pre-clinical research and development in oncology and metabolic disorders. She held an academic appointment at the Gladstone Institutes and most recently the positions of Sr Group Leader at Cytokinetics and of Director of Pharmacology at Arete Therapeutics.
Sylvaine Cases received a MS in bioengineering from the French engineering school AgroParisTech in Paris, majoring in Biochemistry, and a Ph.D. in Molecular Oncology from the University of Paris 7. She completed post-doctoral studies at the Gladstone Institutes/UCSF.
